| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $854M | 0.3% | 2026-06-30 |
| Daniel Loeb | Third Point | $103M | 2.2% | 2026-06-30 |
| Chase Coleman | Tiger Global Management | $87M | 0.4% | 2026-06-30 |
| Dodge & Cox | Dodge & Cox | $49M | 0.0% | 2026-06-30 |
| Stanley Druckenmiller | Duquesne Family Office | $10M | 0.2% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $5M | 0.4% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $5M | 0.0% | 2026-06-30 |
| Wahed Invest | Wahed Invest LLC | $3M | 0.3% | 2026-06-30 |
| Saturna Capital | Amana Mutual Funds Trust | $2M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Danaher Corp. (DHR) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for DHR — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.80 | NEUTRAL |
| Stochastic %K (14) | 0.95 | BUY |
| CCI (20) | -112.43 | BUY |
| Williams %R (14) | -99.05 | BUY |
| MACD (12,26,9) | -1.92 | SELL |
| ROC (10) | -6.89 | SELL |
| Momentum (10) | -14.83 | SELL |
| EMA (10) | 207.37 | SELL |
| SMA (10) | 209.14 | SELL |
| EMA (20) | 207.58 | SELL |
| SMA (20) | 209.64 | SELL |
| EMA (30) | 205.98 | SELL |
| SMA (30) | 206.77 | SELL |
| EMA (50) | 202.38 | SELL |
| SMA (50) | 202.25 | SELL |
| EMA (100) | 198.24 | BUY |
| SMA (100) | 190.27 | BUY |
| EMA (200) | 203.02 | SELL |
| SMA (200) | 201.99 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Diagnostics & Research
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
Average — needs more confirmation before sizing up
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Peer movement computing — it will appear here on its own.
BEARISH 0 buys · 2 sells
Recent: Blair Rainer sold 46948 sh @ $217.77 (2026-08-21); Blair Rainer sold 7755 sh @ $218.73 (2026-08-21)
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.